

Forum from the Archives: Is It Time to Rethink Pediatric ADHD?
Jul 28, 2025
Paul Tough, a contributing writer for the New York Times Magazine known for his insights on education and child development, dives into the ADHD debate. He explores the staggering rise to 7 million diagnoses in the U.S. and questions standard treatments like Ritalin, arguing they focus on behavior, not learning. Tough discusses the need for a new understanding of ADHD, emphasizing tailored approaches and the impact of social factors, especially post-pandemic. His thought-provoking insights challenge conventional perceptions and treatment methods.
AI Snips
Chapters
Books
Transcript
Episode notes
Reconsidering ADHD as a Spectrum
- ADHD is often seen as a chronic medical condition like diabetes, but new science suggests symptoms fall on a continuum.
- Medication improves behavior but may not improve learning or cognition, and effects often dissipate over time.
Adult ADHD Diagnosis During COVID
- Janice was diagnosed with ADHD at 43 during COVID after struggling with daily tasks and dysregulation.
- Her diagnosis helped explain lifelong struggles and required her to stop people-pleasing and accept her limits.
Students' Mixed Feelings on Meds
- High school students described stimulant meds as helping focus but also changing their personality and dulling emotions.
- Many felt medication was a sacrifice needed to manage school rather than a welcomed change.